Clicky

Baudax Bio, Inc.(BXRX)

Description: Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.


Keywords: Pharmaceutical Drugs Euphoriants Psychoactive Drugs Clinical Trial Analgesics Opioids Orthopedic Surgery Neurochemistry Ketones Ketamine Anxiolytics Sodium Channel Blockers Colorectal Surgery Dexmedetomidine

Home Page: www.baudaxbio.com

BXRX Technical Analysis

490 Lapp Road
Malvern, PA 19355
United States
Phone: 484 395 2440


Officers

Name Title
Dr. Geraldine A. Henwood Ph.D. Pres, CEO & Director
Ms. Jillian Dilmore Corp. Controller, Corp. Sec., Interim Principal Financial & Accounting Officer
Ms. Diane Myers Sr. VP of Regulatory & Quality

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.0081
Price-to-Book MRQ: 0.6815
Price-to-Sales TTM: 1.0493
IPO Date: 2019-11-22
Fiscal Year End: December
Full Time Employees: 80
Back to stocks